CYBIN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.346 USD | -2.54% |
|
-6.46% | -15.61% |
Presenter SpeechDouglas Drysdale (Executives)Good morning, everyone, and welcome, and thank yo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Calendar
2024-06-18
- Q4 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.474
CAD
Average target price
6.568
CAD
Spread / Average Target
+1,285.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.61% | 263M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.12% | 22.02B | |
| -17.84% | 20.9B | |
| -9.33% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- CYBN Stock
- News Cybin Inc.
- Transcript : Cybin Inc. - Special Call
